- Conditions
- Metastatic Cancer, Melanoma Cancer, Lung Cancer, Bladder Cancer, Renal Cancer, Head/Neck Cancers
- Interventions
- Stereotactic Body Radiotherapy, Ipilimumab, Nivolumab, Pembrolizumab or Atezolizumab
- Radiation · Biological
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 69 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2027
- U.S. locations
- 10
- States / cities
- Hartford, Connecticut • Basking Ridge, New Jersey • Middletown, New Jersey + 7 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 697–720
of 1,014
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Bladder (Urothelial, Transitional Cell) Cancer, Hematuria
- Interventions
- Headphones, Dwell time 5-10 minutes, Dwell Time more than 10 minutes
- Device · Drug
- Lead sponsor
- Florian Schroeck
- Federal
- Eligibility
- 18 Years and older
- Enrollment
- 1,740 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 5
- States / cities
- Birmingham, Alabama • Chapel Hill, North Carolina • Wilmington, North Carolina + 2 more
- Conditions
- Breast Cancer, Colorectal Cancer, Bladder Cancer, Lung Cancer
- Interventions
- Semi-structured interview
- Behavioral
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2023
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Adenocarcinoma of the Bladder, Distal Urethral Cancer, Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter, Proximal Urethral Cancer, Recurrent Bladder Cancer, Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter, Recurrent Urethral Cancer, Squamous Cell Carcinoma of the Bladder, Stage III Bladder Cancer, Stage III Urethral Cancer, Stage IV Bladder Cancer, Transitional Cell Carcinoma of the Bladder, Urethral Cancer Associated With Invasive Bladder Cancer
- Interventions
- ziv-aflibercept, pharmacological study
- Biological · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2014
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Bladder Cancer
- Interventions
- multivitamin, Placebo
- Dietary Supplement · Other
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2003
- U.S. locations
- 16
- States / cities
- Scottsdale, Arizona • Urbana, Illinois • Cedar Rapids, Iowa + 13 more
- Conditions
- Bladder Cancer
- Interventions
- Sirolimus
- Drug
- Lead sponsor
- The University of Texas Health Science Center at San Antonio
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Superficial Bladder Cancer
- Interventions
- Not listed
- Lead sponsor
- University of Sydney
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 498 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 3
- States / cities
- Kansas City, Kansas • Minneapolis, Minnesota • Rochester, Minnesota
- Conditions
- Melanoma (Excluding Uveal Melanoma), Cervical Carcinoma, Pancreatic Carcinoma, Breast Carcinoma That is Estrogen Receptor, Progesterone Receptor, and Her2 Negative, Hepatocellular Carcinoma, Urothelial Carcinoma, Squamous Cell Carcinoma of the Head and Neck, Nasopharyngeal Carcinoma, Renal Cell Carcinoma, Colorectal Carcinoma, Endometrial Carcinoma, Non-small Cell Lung Carcinoma, Small Cell Lung Cancer, Gastric or Gastroesophageal Junction Adenocarcinoma, Advanced Solid Tumors, Undifferentiated Pleomorphic Sarcoma
- Interventions
- XmAb®23104, Yervoy® (ipilimumab)
- Biological
- Lead sponsor
- Xencor, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 198 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 18
- States / cities
- San Diego, California • Aurora, Colorado • Denver, Colorado + 15 more
- Conditions
- Bladder Cancer
- Interventions
- Not listed
- Lead sponsor
- UNC Lineberger Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 68 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Bladder Cancer, Metastatic Bladder Cancer, Unresectable Bladder Carcinoma, Urothelial Carcinoma
- Interventions
- Geriatric-8 Survey, National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy Bladder Symptom Index-18 (FBISI-18), Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE®)
- Behavioral
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 65 Years and older
- Enrollment
- 180 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Melanoma, Medullary Thyroid Cancer, Sinonasal Undifferentiated Carcinoma, Esthesioneuroblastoma, Bladder Cancer, Testicular Cancer, Glioblastoma Multiforme, Cervical Cancer, Large Cell Neuroendocrine Carcinoma of the Lung, Non Small Cell Lung Cancer, Merkel Cell Carcinoma
- Interventions
- Tarlatamab, Concurrent Radiation Therapy, Sequential Radiation therapy
- Drug · Radiation
- Lead sponsor
- University of Arizona
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 3
- States / cities
- Gilbert, Arizona • Tucson, Arizona • Seattle, Washington
- Conditions
- Urinary Bladder Neoplasms
- Interventions
- Magnetic Resonance Imaging, Gadobutrol intravesical administration (4mM), Ferumoxytol intravesical administration (5 mM)
- Diagnostic Test · Drug
- Lead sponsor
- Jodi Maranchie
- Other
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Pancreatic Cancer, Colo-rectal Cancer, Gastric Cancer, Esophageal Cancer, Bladder Cancer, Ovarian Cancer, Abdominal Surgery Complications
- Interventions
- Multidisciplinary Prehabilitation Program
- Behavioral
- Lead sponsor
- Fox Chase Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 180 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Intermediate Risk Non-Muscle Invasive Bladder Cancer
- Interventions
- Nadofaragene Firadenovec
- Drug
- Lead sponsor
- Ferring Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 454 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2031
- U.S. locations
- 53
- States / cities
- Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 47 more
- Conditions
- Bladder Cancer
- Interventions
- TAS 102
- Drug
- Lead sponsor
- Rahul Parikh
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 2
- States / cities
- Fairway, Kansas • Kansas City, Kansas
- Conditions
- Bladder Cancer, Urinary Bladder Neoplasm, Urologic Neoplasms, Neoplasms, Urinary Bladder Diseases
- Interventions
- Fiducial marker placement, Multiparametric MRI (mpMRI)
- Procedure · Diagnostic Test
- Lead sponsor
- Cedars-Sinai Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 3
- States / cities
- Los Angeles, California • Boston, Massachusetts
- Conditions
- Cancer, Immunotherapy, Advanced Solid Tumors Cancer, Bladder Cancer, TNBC, Triple Negative Breast Cancer, Colorectal Cancer, DMMR Colorectal Cancer, MSI-H Colorectal Cancer, Endometrial Cancer, Head and Neck Cancer, Kidney Cancer, Liver Cancer, NSCLC (Non-small-cell Lung Cancer), Skin Cancer, Melanoma (Skin Cancer)
- Interventions
- Biopsy
- Procedure
- Lead sponsor
- Elephas
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2038
- U.S. locations
- 8
- States / cities
- Fort Smith, Arkansas • Frederick, Maryland • Springfield, Missouri + 4 more
- Conditions
- Urothelial Carcinoma of the Bladder
- Interventions
- Proton therapy, IMRT
- Radiation
- Lead sponsor
- Abramson Cancer Center at Penn Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Bladder Cancer, Cystectomy
- Interventions
- Exercise Training, Nutritional Intervention
- Other · Dietary Supplement
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2027
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- Bladder Cancer
- Interventions
- Financial Incentive to Increase Ambulation
- Other
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Bladder Cancer, Urinary Cancer, Nonmuscle Invasive Bladder Cancer
- Interventions
- specimen samples, questionnaires
- Genetic · Behavioral
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 116 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2013
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Bladder Cancer
- Interventions
- BCG intravesical live (TICE Bacillus Calmette-Guerin (BCG)), PANVAC
- Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2019
- U.S. locations
- 2
- States / cities
- Bethesda, Maryland • New Brunswick, New Jersey
- Conditions
- Non-small Cell Lung Cancer, Bladder Cancer
- Interventions
- CVA21/pembrolizumab
- Biological
- Lead sponsor
- Viralytics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 85 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2020
- U.S. locations
- 9
- States / cities
- Santa Monica, California • Coral Gables, Florida • Niles, Illinois + 6 more
- Conditions
- Urinary Bladder Neoplasms
- Interventions
- Tamoxifen
- Drug
- Lead sponsor
- Seth Lerner
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2012
- U.S. locations
- 1
- States / cities
- Houston, Texas